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Recent studies have shown that immunotherapy clears amyloid beta (Aβ) plaques and
reduces Aβ levels in mouse models of Alzheimer’s disease (AD), as well as in AD patients.
Tangle pathology is also relevant for the neurodegeneration in AD, and our studies have
shown that active immunization with an AD related phospho-tau peptide reduces aggre-
gated tau within the brain and slows the progression of tauopathy-induced behavioral
impairments.Thus, clearance of neuroﬁbrillary tangles and/or their precursors may reduce
synaptic and neuronal loss associated with AD and other tauopathies. So far the mecha-
nisms involved in antibody-mediated clearance of tau pathology are yet to be elucidated.
In this study we have used a mouse brain slice model to examine the uptake and localiza-
tion of FITC labeled anti-tau antibodies. Confocal microscopy analysis showed that the FITC
labeled anti-tau antibody co-stainedwith phosphorylated tau, had a perinuclear appearance
and co-localized with markers of the endosomal/lysosomal pathway. Additionally, tau and
FITC–IgG were found together in an enriched lysosome fraction. In summary, antibody-
mediated clearance of intracellular tau aggregates appears to occur via the lysosomal
pathway.
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INTRODUCTION
The presence of intracellular neuroﬁbrillary tangles (NFT’s) com-
posed of hyperphosphorylated tau is a characteristic feature of
Alzheimer’s disease (AD) and other tauopathies. The causative
role of tau pathology in neurodegeneration has been unequivo-
cally proven with the identiﬁcation of tau mutations in a range
of disorders termed frontotemporal dementia and Parkinsonism
linked to chromosome 17 (FTDP-17; Hutton et al., 1998; Poorkaj
et al., 1998). Therapeutic approaches targeting tau pathology have
concentrated on reducing its level of phosphorylation by mod-
ifying tau kinase and phosphatase activities (Gong et al., 2010;
Medina and Avila, 2010; Piedrahita et al., 2010). A novel approach
developed by our group is to use immunomodulation to clear tau
pathology, akin to what has been tried with reducing amyloid beta
(Aβ) load in transgenic mice and in recent clinical trials (Schenk
et al., 1999; Sigurdsson et al., 2001; Lemere and Masliah, 2010).
We have shown in twomodels with tangle pathology that active or
passive immunization targeting a tauopathy related phospho-tau
epitope, reduces tau aggregates and slows the progression of tangle
relatedmotor deﬁcits (Asuni et al., 2007; Boutajangout et al., 2011)
and prevents cognitive impairments (Boutajangout et al., 2010).
A natural follow up of these studies is to investigate the cellu-
lar mechanisms involved in this phenomenon. The most likely
route for clearance of tau aggregates would appear to be the
endosomal–lysosomal pathway (Asuni et al., 2007). Previously,
it had been shown that lysosomal tau is detected in AD and
control brains (Ikeda et al., 1998), and pathological changes in
the lysosomal pathway in AD are well established (Nixon et al.,
2005). More recently, lysosomal processing has been shown to
inﬂuence tau aggregation and clearance in an inducible tauopathy
cell model (Wang et al., 2009). Moreover, using immuno electron
microscopy techniques,Meeker et al. (1987) showed that antibod-
ies could be detected within lysosomes. Thus, we propose that
the antibody-mediated removal of tau aggregates is facilitated by
clearance through the endosomal–lysosomal pathway (Sigurdsson,
2008, 2009).
Further support for the validity of this view comes from a study
using amousemodel of Parkinson’s disease which was immunized
with α-synuclein or its antibodies, and showed clearance of α-
synuclein aggregates, most likely via lysosomal pathways (Masliah
et al., 2005,2011)Additionally,Tampellini et al. (2007) showed that
anti-Aβ antibodies could clear Aβ aggregates via the endosomal–
lysosomal pathway in a neuronal cell culture system.More recently,
decreased levels of the lysosomal proteases, cathepsinDandL,were
observed in tangle mice receiving tau immunotherapy (Boimel
et al., 2010), which perhaps may be a consequence of diminished
tau pathology.
Another established mechanism for the clearance of cellu-
lar proteins is via the ubiquitin proteasome system (UPS). The
UPS is considered to be mainly involved in the degradation of
short lived, misfolded, and truncated proteins (Pickart, 2004). It
has been known for some time that ubiquitin could be detected
with NFT’s (Mori et al., 1987), and in AD brain tissue, impaired
proteasome peptidase activity has been noted (Keller et al.,
2000). Thus, impairment of the UPS has been proposed to be a
contributing factor for the accumulation of misfolded proteins in
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several neurodegenerative diseases including AD and Parkinson’s
disease.
Similar to other soluble proteins, normal tau, and certain
species of non-aggregated hyperphosphorylated tau are likely
degraded by the ubiquitin proteosome system (Petrucelli and
Dawson, 2004). However, upon aggregation or under patholog-
ical conditions, clearance through the autophagy endosomal–
lysosomal system should be favored. Indeed, prevalent lysosomal
and autophagic vesicles have been detected by ultrastructural
analysis in the JNPL3 tangle mouse model (Lin et al., 2003), as
well as in neuronal cultures that express various tau mutations
(Lim et al., 2001).
Herein, we studied the uptake and localization of FITC labeled
anti-tau antibodies in an organotypic brain slice model derived
from adult homozygous JNPL3 mice with established tau pathol-
ogy. Fixed sliceswere sectioned and stainedwith antibodies against
cellular organelle markers such as early and late endosomes, and
lysosomes, as well as antibodies that recognize pathological and
phosphorylated tau. Additionally, biochemical studies examining
antibody compartmentalization were performed.
MATERIALS AND METHODS
ACUTE BRAIN SLICE MODEL AND FITC–IgG TREATMENT
Brain slices were prepared from adult (15–26months old)
homozygous JNPL3mice (Taconic; Lewis et al., 2000) as described
by Gong et al. (2001), allowed to stabilize at room temperature
for 1 h and incubated with FITC–IgG for 2 h at 35˚C with inter-
mittent oxygenation. The IgG was puriﬁed from an immunized
JNPL3 mouse with a high antibody titer against our phos-tau
immunogen (Tau 379–408[pSer396, 404]; Asuni et al., 2007). FITC
conjugation was performed with the FluoroTag™FITC Conjuga-
tion Kit (Sigma) as per the manufacturer’s protocol. Slices were
either ﬁxed in periodate–lysine–paraformaldehyde buffer (PLP)
for immunohistochemical analysis or frozen for biochemical
analysis.
IMMUNOHISTOCHEMISTRY
Fixed slices were sectioned at 40μm and were stained with the
tau antibodies CP13 (pSer202 epitope) andMC1 (conformational
epitope). Tau antibodies CP13 and MC1 were kindly provided by
Prof. P. Davies, AECOM, New York. Sections were also stained
with antibodies against lysosomal-associated membrane protein
2 (LAMP2; Abl93; Chen et al., 1985) and Rab5, markers of lyso-
somes and early endosomes respectively, kindly provided by Dr.
P. Mathews, Nathan Kline Institute, Orangeburg. All sections were
stainedwith appropriate secondary antibodies conjugated to Texas
Red (Molecular Probes), counterstained with the nuclear marker
Hoechst 33342 (Molecular Probes) and visualized by confocal
microscopy (Zeiss LSM710, Zeiss Plan-Apochromat 63×/1.40 Oil
DIC objective).
LYSOSOME PREPARATION
Frozen slices were homogenized and an enriched lysosome frac-
tion was prepared as per the Lysosome Enrichment Kit for Tissue
andCulturedCells (Pierce). Brieﬂy, brain slices were homogenized
in 1× v/w Lysosome Enrichment Reagent A containing protease
inhibitors. An equal volume of Lysosome Enrichment Reagent B
containing protease inhibitors was then added and the tube mixed
by inverting. Samples were centrifuged at 500× g for 10min at
4˚C. The supernatant obtained was brought to a ﬁnal concentra-
tion of 15% OptiPrep™Media, overlaid on top of a discontinuous
density gradient and spun at 145,000× g for 2 h at 4˚C. Post ultra-
centrifugation, 400μl fractions were removed from around and
including the top visible band that had formed in the gradient of
the ultracentrifuge tube and processed for removal of lysosomes as
indicated in the manufacturer’s protocol (Pierce). Lysosome pel-
lets were resuspended in 2× STOP buffer for western blot analysis.
The enriched lysosome preparation was repeated multiple times
(n = 6).
WESTERN BLOT
Enriched lysosome pellet fractions were resuspended in 2× STOP
buffer (0.25M Tris–HCl, pH 7.5, 2% SDS, 25mM dithiothreitol,
5mMEDTA, 5mMEGTA, 10% glycerol, and 0.01%bromophenol
blue), boiled and loaded onto 8 or 10%polyacrylamide gels.Mem-
branes were probed with antibodies to LAMP2 (Abl93; Chen et al.,
1985, gift from Dr. P. Mathews), IgG–FITC (200-032-037 Jackson
Immunoresearch), or total tau (DAKO A0024). The blots were
incubated with the appropriate peroxidase-conjugated goat anti-
rat, anti-rabbit, or anti-mouse IgG (Jackson Immunoresearch).
Immunoreactive bands were visualized and analyzed by enhanced
chemiluminescence reagent (Thermo Scientiﬁc) using a Fujiﬁlm
LAS4000 imaging system and the Multi Gage software (Fujiﬁlm
Life Science, USA). Immunoblotting for LAMP2, IgG–FITC, and
total tau was performed four separate times.
RESULTS
Organotypic brain slices were prepared and used to determine
the localization of our FITC labeled phos-tau antibody that had
been added to the slice culture. Slices were co-stained with anti-
bodies CP13, which recognizes tau phosphorylated at the Ser202
site (Weaver et al., 2000), and MC1, which detects a patho-
logical conformation of tau that is present in AD brain (Jicha
et al., 1997), and a Texas Red conjugated secondary antibody.
Confocal microscopy images showed extensive but partial co-
localization between FITC–IgG and the tau antibodies CP13 and
MC1 (Figure 1). Furthermore, we determined that the FITC–IgG
was completely associated with cellular markers of lysosomes,
LAMP2, and early endosomes, Rab5, with perinuclear vesicles
as the main areas of co-staining. In wild type mice, limited
non-speciﬁc FITC–IgG binding was observed (Figure 1 bottom
panel).
A higher magniﬁcation confocal microscope image of brain
slices from a JNPL3 mouse incubated with FITC labeled phos-tau
antibody and co-stained with LAMP2 clearly shows the perinu-
clear regions of co-staining. The delineated shape of the cell has
a neuronal morphology and indicates that neurons are capable of
taking up our FITC labeled phos-tau antibody (Figure 2).
To examine antibody compartmentalization, we next prepared
an enriched lysosome fraction from our FITC–IgG treated JNPL3
brain slices. Fractions were removed post separation and analyzed
by western blot. Figure 3 indicates enriched lysosome fractions
obtained from two separate mice, A and B respectively. Frac-
tions (400μl) were obtained from around and inclusive of the
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FIGURE 1 | FITC labeled IgG from a high titer mouse co-localizes with
phosphorylated and pathological tau within the endosomal/lysosomal
system. Confocal microscope images of brain slice sections from JNPL3
transgenic mice andWT (bottom panel) mice. Slices were incubated with
FITC–IgG from a high titer Tau 379–408[pSer396, 404] immunized mouse
(green) and after sectioning co-stained with an antibody to LAMP2 (red), a
marker of late endosomes/lysosomes, and an antibody to Rab5 (red), a
marker of early endosomes and the nuclear stain Hoechst 33342. The
merged images indicate areas of co-localization between FITC–IgG and
endosomes and lysosomes (orange/yellow), mostly in perinuclear areas.
Slices were also co-stained with an antibody to MC1 (red), which recognizes
a disease related conformational tau epitope and CP13 (red) which
recognizes tau pSer202. The merged images indicate areas of co-localization
between FITC–IgG and pathological tau (yellow), mostly in perinuclear areas.
Minimal staining was observed in theWT mouse. Scale bar=10μm.
FIGURE 2 | Neuronal co-localization of FITC–IgG and LAMP2. High
magniﬁcation confocal microscope images of brain slice sections from a
JNPL3 transgenic mouse. Brain slices were incubated with FITC–IgG from a
high titer Tau 379–408[pSer396, 404] immunized mouse (green) and after
sectioning co-stained with an antibody to LAMP2 (red), which is a marker of
late endosomes and lysosomes. The merged image indicates areas of
co-localization (green/yellow) between FITC–IgG and late
endosomes/lysosomes, mainly in perinuclear areas. The neuronal
morphology is clearly delineated by the regions of staining.
top visible band in the ultracentrifuge tube. Immunoblotting with
an antibody to LAMP2, a marker of lysosomes, showed LAMP2
immunoreactivity in fractions A2, B1, B2, and B3. Fraction A1 is
FIGURE 3 | FITC labeled IgG from a high titer mouse and tau are
present in enriched lysosome fractions. Immunoblotting analysis of
enriched lysosome fractions from two separate JNPL3 mice brain
preparations is shown, A and B respectively. Brain slices (400μm) were
incubated with FITC–IgG from a high titer Tau 379–408[pSer396, 404]
immunized mouse for 2 h. Post treatment slices were processed to obtain
an enriched lysosome fraction. Several fractions were obtained and the
presence of lysosomes was conﬁrmed in LAMP2 positive fractions A2, B1,
B2, and B3. Mouse kidney lysate was used as a positive control. The kidney
control is not a puriﬁed kidney preparation but a whole organ lysate, hence
it has more background staining when compared to the enriched lysosome
fractions from brain. Lysosome fractions were also immunoblotted for
FITC–IgG. Fractions A2, B1, B2, and B3 were positive for FITC–IgG.To test if
the lysosome fractions also contained tau, the FITC–IgG blot was reprobed
with an antibody to total tau (DAKO A0024). Lysosome fractions A2, B1, B2,
B3, and kidney lysate, all were positive for tau. Importantly, most of the
FITC–IgG was detected in fractions with the highest levels of tau (A2 and
B1). Overall, these ﬁndings are in accordance with the histological ﬁndings.
most likely only OptiPrep™media without any lysosomes. Mouse
kidney lysates were also run as a positive control. The kidney lysate
is a whole tissue homogenate rather than a lysosome fraction
(Figure 3). Immunostaining of the enriched lysosome fractions
with an anti-FITC–IgG antibody showed more intense reactiv-
ity in fractions A2 and B1, indicating that our FITC conjugated
antibody was taken up by the brain slices and present in the lyso-
some preparations (Figure 3). To test if the lysosome fractions also
contained tau, the FITC–IgG blot was reprobed with an antibody
to total tau (DAKO A0024). Lysosome fractions A2, B1, B2, and
B3 were all positive for tau. Fraction A1 was weakly positive for
tau, probably due to the fraction not being completely pure. And
mouse kidney lysates were also tau positive since tau is known to
be present in non-neuronal tissue (Gu et al., 1996; Figure 3).
JNPL3 mice overexpress mutant tau (P301L) and develop
extensive tau pathology (Lewis et al., 2000). A potential route
involved in the clearance of pathological tau is the endosomal–
lysosomal pathway, hence we next examined if markers of the
lysosomal pathway were upregulated in these animals. Enriched
lysosome fractions were prepared fromwild type and JNPL3 brain
slices. The presence of lysosomes was conﬁrmed in LAMP2 pos-
itive fractions from both wild type and JNPL3 mice (Figure 4).
The transgenic mice appeared to have more lysosomes than wild
type mice. Additionally, immunoblotting of lysosome fractions
with the total tau antibody showed the presence of tau in both
wild type and transgenic mice, but as expected lysosomes from the
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FIGURE 4 | Non-immunized JNPL3 mice have more lysosomes than
WT mice and these contain tau. Brain slices (400μm) were processed to
obtain an enriched lysosome fraction. (A) Representative immunoblot
showing the presence of lysosomes (LAMP2) and tau (DAKO A0024) was
conﬁrmed in fractions from bothWT and JNPL3 mice. Mouse kidney lysate
was used as a positive control. (B) Quantiﬁcation of immunoblots indicated
that non-immunized JNPL3 mice had fourfold more lysosomes thanWT
mice, with corresponding eightfold higher amounts of tau (n =3 separate
experiments).
latter group had much more tau than lysosomes obtained from
wild type brain (Figure 4).
DISCUSSION
The idea of using immunotherapy to treat neurodegenerative dis-
orders such as AD is gaining more momentum. Several active
and passive immunotherapy approaches are under investigation
in clinical trials with the aim of accelerating Aβ clearance from the
brain of AD patients. The most advanced of these immunological
approaches is bapineuzumab, composed of a humanized anti-Aβ
monoclonal antibody, which is being tested in a Phase III trial
(Frisardi et al., 2010).
To date the mechanism by which immunomodulation can
result in a clearance of tau pathology has not been elucidated.
In fact a major caveat to accepting the validity of immunotherapy
has been the notion that since the brain is an immunoprivileged
site, it is not amenable to a vaccine based treatment. With par-
ticular respect to tau immunotherapy, it did not seem logical
to many that antibodies could access intracellular proteins such
as tau. The rationale for and potential mechanisms involved in
antibody-mediated clearance of tau aggregates has been outlined
in (Sigurdsson, 2008, 2009). Brieﬂy, active or passive immuniza-
tion targeting pathological tau should promote the clearance of
tau aggregates and aid in restoring or saving neuronal function.
To facilitate this, antibodies must ﬁrst enter the CNS. In fact anti-
body entry into the CNS has been shown under normal conditions
(Nerenberg and Prasad, 1975), and also antibodies can be actively
transported via adsorptive mediated transcytosis (Zlokovic et al.,
1990; Bickel, 1995). Additionally, the blood brain barrier (BBB)
is known to be compromised in neurodegenerative diseases such
as AD (Zlokovic, 1997), and we have detected increased perme-
ability of the BBB in JNPL3 mice with advanced tau pathology
(Asuni et al., 2007). It is also well established that neurons have
several receptors that can bind IgG,which can then be internalized
via receptor-mediated endocytosis (Sigurdsson, 2008, 2009). The
antibodiesmay also diffuse through damagedmembranes. Impor-
tantly,we previously reported that the sameFITC–IgGpreparation
entered neurons within the brain and bound to pathological tau
following injection into the carotid artery (Asuni et al., 2007).
Once the tau antibodies have entered the brain and are inter-
nalized the most likely method of clearance of phosphorylated
tau oligomers/aggregates would be via the endosomal-autophagy-
lysosomal pathways. This is based on evidence fromultrastructural
analysis of JNPL3 mice which has shown the presence of axonal
spheroids containing ﬁlamentous tau as well as autophagic and
lysosomal vacuoles (Lin et al., 2003), and the fact that antibodies
have also been detected within lysosomes (Meeker et al., 1987).
The data from the present study shows that in a JNPL3 mouse
brain slice model system, puriﬁed IgG from a mouse immunized
with the phos-tau peptide (Tau 379–408[pSer396,404] is able to co-
localize with tau species that are hyperphosphorylated and have a
pathological conformation – CP13 and MC1 positive. There was
no discernable MC1 or puriﬁed IgG immunostaining in wild type
brain slices, indicating that our phos-tau immunized mice had
developed antibodies to pathological tau species and the antibod-
ies were preferentially internalized in neurons with tau aggregates.
The brain slice model provides a unique system to help analyze
antibody uptake, given the fact that we have circumvented the
requirement for antibodies to cross the BBB.
Themost likelymechanism for antibody-mediated clearance of
large and probably long lived tau aggregates is via the endosomal–
autophagy–lysosomal pathways, rather than the UPS (Sigurdsson,
2009). Thus whenwe stained JNPL3 brain slices with antibodies to
Rab5 and LAMP2,markers of early endosomes and lysosomes, we
clearly saw that our labeled puriﬁed IgG did in fact co-localize with
endosomal and lysosomal organelles. We are currently exploring
the potential involvement of autophagic pathways.
Proteasome activity has been found to be decreased in AD
brain tissue (Keller et al., 2000). A potential reason for this
was reported by Keck and colleagues. They showed that the
inhibition of the endogenous proteasome system in AD brain
tissue was due to the binding of PHF tau to the 20S core
proteasome (Keck et al., 2003). We would expect the capac-
ity of the proteasomal degradation pathway has likely been
exceeded in the aged JNPL3 mice with extensive tau pathol-
ogy, and the endosomal–autophagy–lysosomal pathways should
be the preferred mechanism for removing tau aggregates, sim-
ilar to what has been reported in an inducible tauopathy cell
model (Wang et al., 2010). Also, the aggregates are too large to
enter the proteasome (Sigurdsson, 2009). However, it is interest-
ing in this context that high afﬁnity antibody receptor on ubiq-
uitin E4 ligase (TRIM21) has recently been identiﬁed (Mallery
et al., 2010). This opens up the possibility that tau antibodies
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may facilitate clearance of soluble misfolded tau, which may be
particularly relevant under prophylactic conditions to prevent
further aggregation.
Our immunostaining data supports our idea that the clear-
ance of tau aggregates can proceed via the endosomal–lysosomal
system. This is also supported by ultrastructural analysis of two
transgenic mouse lines. In the JNPL3 mouse model, electron
microscopy analysis has shown lysosomal and autophagic vesi-
cles to be associated with tau ﬁlaments (Lin et al., 2003), and in
a transgenic mouse expressing four microtubule binding repeats
and three FTDP-17 mutations, there was evidence of increased
numbers of morphologically abnormal lysosomes (Lim et al.,
2001). Additional evidence for the involvement of the endosomal–
lysosomal pathway was seen in the biochemical preparations of
enriched lysosomes from JNPL3mouse slices treated with puriﬁed
and FITC labeled IgG. Enriched lysosome fractions were positive
for FITC–IgG as well as tau protein, and as anticipated, JNPL3
mice had more lysosomes containing tau than wild type mice. It is
unlikely that FITC labeled IgG would be present in other enriched
organelle fractions such asGolgi ormitochondrial fractions. There
are no reports of IgG being detected in these fractions in contrast
to lysosomes (Meeker et al., 1987). However, these are important
controls and should be examined in future studies.
Recently, two studies reported that tau pathology could spread
through different brain regions. Frost et al. (2009) showed that
cultured neuronal cells could take up aggregated tau and these
extracellular tau aggregates could induce ﬁbril formation intra-
cellularly. Additionally, they showed that the aggregated tau could
be transmitted between co-cultured cells (Frost et al., 2009). How
endocytosed extracellular aggregates can promote ﬁbrillization of
a cytoplasmic protein is not known. But we can envision that tau
antibody treatment could readily bind to extracellular aggregates
and promote their clearance in a manner similar to what has been
proposed for antibodies targeting Aβ (Sigurdsson, 2009), and thus
prevent the propagation of misfolded tau through the brain. Just
as Frost and colleagues predicted, Clavaguera et al. (2009) demon-
strated that injecting brain extract fromamousewith the FTDP-17
P301S tau mutation into the brain of a transgenic mouse express-
ing unmutated human tau, led to the formation of tau ﬁlaments
and the spreading of pathology from one brain region to another.
Again, we can only speculate at the mechanism responsible for the
spreading of tau pathology. Mutant tau could potentially be acting
as a seeding or nucleating factor for aggregates. Treatment with
tau antibodies would again be beneﬁcial as they could disrupt this
event and so prevent the spread of tau pathology between different
brain regions. The spread of amyloidosis within the affected organ
is likely to be similar for all amyloid diseases (Sigurdsson et al.,
2002). Hence, both tau and Aβ can be targeted with immunother-
apy regardless of whether the main pool of aggregates is intra or
extracellular.
Overall, based on the ﬁndings from our brain slice system we
can conﬁrm that the endosomal–lysosomal pathway is involved in
antibody-mediated clearance of tau aggregates.
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